The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer

To learn if cemiplimab can help to control dMMR colon cancer.

Trial Details

NCT ID
NCT05961709
Phase
PHASE2
Sponsor
M.D. Anderson Cancer Center
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Cemiplimab
Locations (sample)
  • Gilbert, Arizona, United States|33.35283,-111.78903
  • Jacksonville, Florida, United States|30.33218,-81.65565
  • New Orleans, Louisiana, United States|29.95465,-90.07507
  • Camden, New Jersey, United States|39.92595,-75.11962
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Participants are eligible to be included in the study only if all of the following criteria apply:
  • Age ≥18 years
  • Histological confirmation of colon adenocarcinoma, as determined by pathology review (inferior colon margin defined as \>10 cm from anal verge).
  • Colon cancer that is deficient in mismatch repair (dMMR) or microsatellite Instability high (MSI-H) as determined by one of three methods:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →